United States Personalized Cancer Vaccines Market Set for Breakthrough Growth with Innovative Therapies Revolutionizing Oncology Care 2025 | Major key players - BioNTech SE, Merck & Co., Inc., Moderna, Inc.

Market Size and Growth:

The Global Personalized Cancer Vaccines Market size reached US$ 11.33 Billion in 2024 from US$ 10.21 Billion in 2023 and is expected to reach US$ 30.12 Billion by 2033, growing at a CAGR of 11.5% during the forecast period 2025-2033.

The Personalized Cancer Vaccines Market report by DataM Intelligence provides insights into the latest trends and developments in the market. This report identifies the key growth opportunities in the market and provides recommendations for market participants to capitalize on these opportunities. Overall, the Personalized Cancer Vaccines market report is an essential resource for market participants who are looking to gain a comprehensive understanding of the market and identify opportunities for growth.

Download a Free sample PDF (Use Corporate email ID to Get Higher Priority) at: https://datamintelligence.com/download-sample/personalized-cancer-vaccines-market?sz

The Personalized Cancer Vaccines Market focuses on developing customized immunotherapies designed to stimulate a patient's immune system against tumor-specific antigens. These vaccines are tailored using genetic and molecular profiling to target unique cancer mutations, enhancing treatment precision and effectiveness. Growing demand is driven by advancements in genomics, biotechnology, and rising cancer prevalence worldwide.

Recent Key Developments of United States (U.S):

Clinical Trial Success for Kidney Cancer: A phase 1 trial at Dana-Farber Cancer Institute showed that a personalized cancer vaccine generated successful anti-cancer immune responses in all nine patients with Stage III or IV clear cell renal cell carcinoma. (July 2025)

Universal Cancer Vaccine Research: A University of Florida study in mice demonstrated that a generalized mRNA vaccine, not tailored to a specific tumor, could stimulate a strong immune response against cancer, potentially paving the way for a universal "off-the-shelf" vaccine. (July 2025)

Advancements in Melanoma Treatment: An updated formulation and delivery of the NeoVax personalized cancer vaccine, called NeoVaxMI, was shown in a Dana-Farber clinical trial to be safe, feasible, and to improve the immune response in melanoma patients. (July 2025)

Phase 1 Trial for Multi-Cancer Vaccine: Early results from a Phase 1 trial at Mount Sinai for the personalized multi-peptide neoantigen cancer vaccine, PGV001, showed it was safe and induced a strong immune response in a small group of patients with various cancers. (March 2025, with ongoing developments)

Continued Clinical Progress: Ongoing clinical trials are exploring personalized cancer vaccines in combination with other immunotherapies for various cancers, including a phase II trial for an mRNA-based vaccine in kidney cancer and a phase I/II trial for a peptide vaccine in colorectal and pancreatic cancer, with initial results expected later in 2025. (August-September 2025)

Key Players:

BioNTech SE
Merck & Co., Inc.
Moderna, Inc.
Gritstone Bio
Transgene
CureVac SE
Nouscom
Evaxion A/S.

This Report Covers:

✔ Go-to-market Strategy.

✔ Neutral perspective on the market performance.

✔Development trends, competitive landscape analysis, supply side analysis, demand side analysis, year-on-year growth, competitive benchmarking, vendor identification, and other significant analysis, as well as development status.

✔Customized regional/country reports as per request and country level analysis.

✔ Potential & niche segments and regions exhibiting promising growth covered.

✔ Analysis of Market Size (historical and forecast), Total Addressable Market (TAM), Serviceable Available Market (SAM), Serviceable Obtainable Market (SOM), Market Growth, Technological Trends, Market Share, Market Dynamics, Competitive Landscape and Major Players (Innovators, Start-ups, Laggard, and Pioneer).

Looking For Full Report? Get it Here: https://www.datamintelligence.com/buy-now-page?report=personalized-cancer-vaccines-market

Market Segmentation:

By Vaccine Type: Dendritic Cell Vaccines, mRNA-based Vaccines, DNA-based Vaccines, Peptide-based Vaccines, Viral Vector Vaccines, Protein-based Vaccines and Others.

By Indication: Melanoma, Lung Cancer, Pancreatic Cancer, Breast Cancer, Colorectal Cancer, Glioblastoma, Prostate Cancer, Cervical Cancer and Others.

By End-User: Hospitals, Cancer Research Centers, Biotechnology & Pharma Companies, Academic Institutions and Others.

Regional Analysis:

⇥ North America (U.S., Canada, Mexico)

⇥ Europe (U.K., Italy, Germany, Russia, France, Spain, The Netherlands and Rest of Europe)

⇥ Asia-Pacific (India, Japan, China, South Korea, Australia, Indonesia Rest of Asia Pacific)

⇥ South America (Colombia, Brazil, Argentina, Rest of South America)

⇥ Middle East & Africa (Saudi Arabia, U.A.E., South Africa, Rest of Middle East & Africa)

Speak to Our Analyst and Get Customization in the report as per your requirements: https://datamintelligence.com/customize/personalized-cancer-vaccines-market?sz

Chapter Outline

⏩ Market Overview: It contains five chapters, as well as information about the research scope, major manufacturers covered, market segments, Personalized Cancer Vaccines market segments, study objectives, and years considered.

⏩ Market Landscape: The competition in the Global Personalized Cancer Vaccines Market is evaluated here in terms of value, turnover, revenues, and market share by organization, as well as market rate, competitive landscape, and recent developments, transaction, growth, sale, and market shares of top companies.

⏩ Companies Profiles: The global Personalized Cancer Vaccines market's leading players are studied based on sales, main products, gross profit margin, revenue, price, and growth production.

⏩ Market Outlook by Region: The report goes through gross margin, sales, income, supply, market share, CAGR, and market size by region in this segment. North America, Europe, Asia Pacific, Middle East & Africa, and South America are among the regions and countries studied in depth in this study.

⏩ Market Segments: It contains the deep research study which interprets how different end-user/application/type segments contribute to the Personalized Cancer Vaccines Market.

⏩ Market Forecast: Production Side: In this part of the report, the authors have focused on production and production value forecast, key producers forecast, and production and production value forecast by type.

⏩ Research Findings: This section of the report showcases the findings and analysis of the report.

⏩ Conclusion: This portion of the report is the last section of the report where the conclusion of the research study is provided.

Unlock 360° Market Intelligence with DataM Subscription Services: https://www.datamintelligence.com/reports-subscription

People Also Ask:

◆ How big is the Personalized Cancer Vaccines Market in 2025?
◆ What is the projected growth rate of the Personalized Cancer Vaccines Market through 2033?
◆ Who are the key players in the Personalized Cancer Vaccines Market?
◆ Which region is expected to dominate the industry during the forecast period?

Contact Us -
Company Name: DataM Intelligence
Contact Person: Sai Kiran
Email: Sai.k@datamintelligence.com
Phone: +1 877 441 4866
Website: https://www.datamintelligence.com

About Us -
DataM Intelligence is a Market Research and Consulting firm that provides end-to-end business solutions to organizations from Research to Consulting. We, at DataM Intelligence, leverage our top trademark trends, insights and developments to emancipate swift and astute solutions to clients like you. We encompass a multitude of syndicate reports and customized reports with a robust methodology.
Our research database features countless statistics and in-depth analyses across a wide range of 6300+ reports in 40+ domains creating business solutions for more than 200+ companies across 50+ countries; catering to the key business research needs that influence the growth trajectory of our vast clientele.

This release was published on openPR.